Generate Biomedicines (NASDAQ:GENB) Reaches New 1-Year High – Here’s What Happened

Generate Biomedicines Inc (NASDAQ:GENB) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $18.41 and last traded at $18.6240, with a volume of 199688 shares traded. The stock had previously closed at $17.72.

Analyst Ratings Changes

Several brokerages recently commented on GENB. Morgan Stanley increased their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings initiated coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They set a “sell (d)” rating on the stock. Finally, HC Wainwright boosted their price objective on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Down 20.8%

The firm’s 50-day simple moving average is $15.23. The firm has a market capitalization of $2.07 billion and a P/E ratio of -10.15.

Generate Biomedicines (NASDAQ:GENB) last issued its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. Equities analysts anticipate that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System bought a new stake in Generate Biomedicines in the 2nd quarter worth approximately $96,000. Susquehanna International Group LLP purchased a new stake in Generate Biomedicines during the 2nd quarter valued at $196,000. AXQ Capital LP bought a new position in shares of Generate Biomedicines during the 2nd quarter valued at $218,000. Bank of New York Mellon Corp purchased a new position in shares of Generate Biomedicines in the 2nd quarter worth $967,000. Finally, Braidwell LP purchased a new position in shares of Generate Biomedicines in the 2nd quarter worth $55,398,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.